BioMarin也迅速跟进迭代研发，其升级版在研产品BMN333同样旨在实现周剂注射。早期临床结果显示BMN333的AUC水平高于其他长效CNP研究的3倍以上，公司研发主管Greg Friberg表示该药对标的正是TransCon-CNP。
Ifab expected to adopt changes at meeting this weekend
。关于这个话题，heLLoword翻译官方下载提供了深入分析
You can find royalty free images, audio, and video without having to subscribe to another service.，推荐阅读heLLoword翻译官方下载获取更多信息
This essay will appear in our forthcoming book, “Making the Modern Laboratory,” to be published later this year.，更多细节参见safew官方版本下载